A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Trial Profile

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2014

At a glance

  • Drugs Fampridine (Primary)
  • Indications Neurological disorders; Stroke complications
  • Focus Adverse reactions
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2013 New trial record
    • 14 Oct 2013 Results were presented at the Annual Meeting of the American Neurological Association in October 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top